9月30日盘中,微创医疗(00853)股价出现大涨,最高上涨16.67%,截至发稿时已累计上涨16.82%,报7.4港元,引发市场关注。
消息面上,国家药品监督管理局日前表态,将全力促进医疗器械研发创新,推动科研成果尽快转化为创新产品,同时支持创新药械进医院并纳入医保。这为医疗器械企业如微创医疗等带来利好。
财报数据显示,微创医疗在创新业务领域持续保持高速增长,大动脉及外周介入业务、神经介入业务、结构心脏业务和手术机器人业务等营收均有不同程度的大幅提升,研发方面也进行了一定调整,提高了效率。
目前股价大涨的具体原因尚未可知,但国家政策利好和公司自身创新领域表现抢眼或是其中重要因素。分析人士预计,前景看好的创新型医疗企业还将受到青睐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.